Pilot study of the effects of taprostene (CG 4203) in patients with advanced peripheral arterial disease.
Darius
H
H
Department of Medicine II, Johannes-Gutenberg University, Mainz, Federal Republic of Germany.
Kopp
H
H
Mulfinger
A
A
Spielberger
M
M
Todt
M
M
Schuster
C J
CJ
Meyer
J
J
D001157:Arterial Occlusive Diseases / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D011464:Epoprostenol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use* / Q000031:analogs & derivatives; D005260:Female; D005483:Flushing / Q000139:chemically induced; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D011465:Prostaglandins, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D002317:Cardiovascular Agents; D011465:Prostaglandins, Synthetic; C039188:taprostene; D011464:Epoprostenol